Home/Filings/3/0000899243-19-025451
3//SEC Filing

TLS Beta Pte. Ltd. 3

Accession 0000899243-19-025451

CIK 0001706431other

Filed

Oct 9, 8:00 PM ET

Accepted

Oct 10, 5:52 PM ET

Size

12.2 KB

Accession

0000899243-19-025451

Insider Transaction Report

Form 3
Period: 2019-10-10
Holdings
  • Series A-1 Preferred Stock

    (indirect: See footnote)
    Common Stock (3,333,333 underlying)
  • Series B Preferred Stock

    (indirect: See footnote)
    Common Stock (1,666,666 underlying)
Holdings
  • Series B Preferred Stock

    (indirect: See footnote)
    Common Stock (1,666,666 underlying)
  • Series A-1 Preferred Stock

    (indirect: See footnote)
    Common Stock (3,333,333 underlying)
Holdings
  • Series A-1 Preferred Stock

    (indirect: See footnote)
    Common Stock (3,333,333 underlying)
  • Series B Preferred Stock

    (indirect: See footnote)
    Common Stock (1,666,666 underlying)
Holdings
  • Series A-1 Preferred Stock

    (indirect: See footnote)
    Common Stock (3,333,333 underlying)
  • Series B Preferred Stock

    (indirect: See footnote)
    Common Stock (1,666,666 underlying)
Footnotes (2)
  • [F1]The preferred stock is convertible into the Issuer's common stock on a one-for-one basis at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.
  • [F2]The securities reported herein are directly held by TLS Beta Pte. Ltd, which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

Issuer

Vir Biotechnology, Inc.

CIK 0001706431

Entity typeother
IncorporatedSingapore

Related Parties

1
  • filerCIK 0001673754

Filing Metadata

Form type
3
Filed
Oct 9, 8:00 PM ET
Accepted
Oct 10, 5:52 PM ET
Size
12.2 KB